S3 Ep38: Speaking Out About MPNs
Cancer Horizons12 Aug 2020

S3 Ep38: Speaking Out About MPNs

Myeloproliferative neoplasms, or MPNs, are not a common type of blood cancer, occurring in approximately 300,00 individuals in the US, according to Dr. Ruben Mesa. In this episode of the “CURE Talks Cancer” podcast, we spoke with Mesa about an MPN diagnosis, what patients need to know and why it is important to become informed in order to improve patient-physician conversations. “My biggest piece of advice is to learn a lot about your disease and also to make notes for yourself both in terms of what you have, what they expect, what questions you have so that you can relay those to your health care provider and really help to overcome that gap in knowledge and understanding,” he said, adding that MPNs are a type of cancer often not known about. “I find that there can be tremendous distress for individuals because of their lack of familiarity with such a disease,” Mesa explained. “For many individuals, when they are diagnosed with this, it's the first time they've heard about it and they have never known anyone else that has had the disease. So they don't have a good frame of reference. That creates a tremendous amount of uncertainty and distress. The more we can alleviate that, the more individuals are able to come to at least a comfortable understanding of their disease and work to try to move past that.”

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(295)

S7 Ep2: Breaking Down Metastatic Triple-Negative Breast Cancer Treatments

S7 Ep2: Breaking Down Metastatic Triple-Negative Breast Cancer Treatments

CURE sat down with Dr. Natalie S. Berger for the latest episode of the “Cancer Horizons” podcast to discuss frontline treatment options for patients with metastatic triple-negative breast cancer. Berg...

31 Des 202514min

S7 Ep1: The Importance of Spotting Endometrial Cancer

S7 Ep1: The Importance of Spotting Endometrial Cancer

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.

18 Mar 202510min

S6 Ep23: ROS1+ Non-Small Cell Lung Cancer: Progress in Care

S6 Ep23: ROS1+ Non-Small Cell Lung Cancer: Progress in Care

17 Sep 202419min

S6 Ep22: Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

S6 Ep22: Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma. And finally, we’ll discuss another ca...

4 Mar 20247min

S6 Ep21: Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

S6 Ep21: Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, an...

4 Mar 202410min

S6 Ep20: FDA Approvals from February 2024

S6 Ep20: FDA Approvals from February 2024

Last week, the Food and Drug Administration (FDA) approved four different therapies in the oncology space — one of which, Amtagvi, marks the first cellular therapy for the treatment of solid cancers. ...

23 Feb 20246min

S6 Ep19: Pancreatic Cancer Approval, Expert Discussion on Cancer Vaccine Development

S6 Ep19: Pancreatic Cancer Approval, Expert Discussion on Cancer Vaccine Development

Last week, we saw some FDA approvals for a new drug regimens, as well as some expert opinion about cancer vaccines. Additionally research touched upon the potential benefit of concurrent ctDNA and tum...

19 Feb 20249min

S6 Ep18: Guidelines for Childhood Neuroblastoma, FDA Decisions and More

S6 Ep18: Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews. Also last week, we covered researc...

12 Feb 20247min

Populært innen Vitenskap

fastlegen
tingenes-tilstand
jss
forskningno
rekommandert
vett-og-vitenskap-med-gaute-einevoll
sinnsyn
villmarksliv
liberal-halvtime
tomprat-med-gunnar-tjomlid
fjellsportpodden
rss-nysgjerrige-norge
rss-rekommandert
diagnose
rss-skogkurs-podden
rss-kunstig-intelligens-med-elisabeth-maren-og-morten
dekodet-2
rss-overskuddsliv
hva-er-greia-med
rss-inn-til-kjernen-med-sunniva-rose